Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
To accelerate the development of next-generation radioconjugates to treat cancer
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Subscribe To Our Newsletter & Stay Updated